Assignee
NLS 1 PHARMA AG
CH·1 granted patent·2 pending applications·0 citations·filing 2017–2019
Top patents by PatentIndex Score
3 records- 0159US2019328714A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS 1 PHARMA AG·Filed 2019·Application pending·0 cites
- 0252US2017216258A1Mazindol combination in the treatment of attention-deficit/hyperactivityNLS-1 PHARMA AG·Filed 2017·Application pending·0 cites
- 0344US11207271B2Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)NLS 1 PHARMA AG·Filed 2017·Granted Dec 28, 2021·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when NLS 1 PHARMA AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →